PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 1997 July; 41(7): 1413–1422.
PMCID: PMC163932

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.

Full Text

The Full Text of this article is available as a PDF (171K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chulay JD, Haynes JD, Diggs CL. Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol. 1983 Feb;55(1):138–146. [PubMed]
  • Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993 May;31 (Suppl 500):149–158. [PubMed]
  • Dieckmann A, Jung A. Stage-specific sensitivity of Plasmodium falciparum to antifolates. Z Parasitenkd. 1986;72(5):591–594. [PubMed]
  • Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. [PMC free article] [PubMed]
  • Fontanet AL, Walker AM. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am J Trop Med Hyg. 1993 Oct;49(4):465–472. [PubMed]
  • Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, Kalense P, M'Hango A, Parry D, Poltera AA, et al. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg. 1993 Feb;48(2):193–197. [PubMed]
  • Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983;61(2):299–305. [PubMed]
  • Harinasuta T, Viravan C, Reid HA. Sulphormethoxine in chloroquine-resistant falciparum malaria in Thailand. Lancet. 1967 May 27;1(7500):1117–1119. [PubMed]
  • Alin MH, Björkman A, Ashton M. In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):635–637. [PubMed]
  • Hien TT, White NJ. Qinghaosu. Lancet. 1993 Mar 6;341(8845):603–608. [PubMed]
  • Howard RJ, Gilladoga AD. Molecular studies related to the pathogenesis of cerebral malaria. Blood. 1989 Dec;74(8):2603–2618. [PubMed]
  • Jiang JB, Li GQ, Guo XB, Kong YC, Arnold K. Antimalarial activity of mefloquine and qinghaosu. Lancet. 1982 Aug 7;2(8293):285–288. [PubMed]
  • Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3200–3203. [PubMed]
  • Kremsner PG, Winkler S, Brandts C, Graninger W, Bienzle U. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg. 1993 Nov;49(5):650–654. [PubMed]
  • Kwiatkowski D, Molyneux ME, Stephens S, Curtis N, Klein N, Pointaire P, Smit M, Allan R, Brewster DR, Grau GE, et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med. 1993 Feb;86(2):91–98. [PubMed]
  • Landau I, Chabaud A, Cambie G, Ginsburg H. Chronotherapy of malaria: an approach to malaria chemotherapy. Parasitol Today. 1991 Dec;7(12):350–352. [PubMed]
  • Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Charoenlarp P, Canfield C, Kyle DE. Treatment of acute uncomplicated falciparum malaria with a short course of artesunate followed by mefloquine. Southeast Asian J Trop Med Public Health. 1993 Jun;24(2):230–234. [PubMed]
  • Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996 Jan;54(1):62–66. [PubMed]
  • Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet. 1987 Nov 7;2(8567):1052–1055. [PubMed]
  • Luxemburger C, Nosten F, Raimond SD, Chongsuphajaisiddhi T, White NJ. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg. 1995 Nov;53(5):522–525. [PubMed]
  • Mapaba E, Hellgren U, Landberg-Lindgren A, Rombo L. Susceptibility of Plasmodium falciparum to quinine in vitro: effects of drug concentrations and time of exposure. Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):85–89. [PubMed]
  • Martin DC, Arnold JD. The effect of parasite populations on the curative action of pyrimethamine. Trans R Soc Trop Med Hyg. 1968;62(3):379–384. [PubMed]
  • Meek SR, Doberstyn EB, Gaüzère BA, Thanapanich C, Nordlander E, Phuphaisan S. Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. Am J Trop Med Hyg. 1986 Mar;35(2):246–250. [PubMed]
  • Murphy JR, Clyde DF, Herrington DA, Baqar S, Davis JR, Palmer K, Cortese J. Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy. Antimicrob Agents Chemother. 1990 Apr;34(4):676–679. [PMC free article] [PubMed]
  • Nosten F, Imvithaya S, Vincenti M, Delmas G, Lebihan G, Hausler B, White N. Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine. Bull World Health Organ. 1987;65(6):891–896. [PubMed]
  • Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Eh JP, Chongsuphajaisiddhi T, White NJ. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 1994 Oct;170(4):971–977. [PubMed]
  • Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991 May 11;337(8750):1140–1143. [PubMed]
  • Pasvol G, Newton CR, Winstanley PA, Watkins WM, Peshu NM, Were JB, Marsh K, Warrell DA. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg. 1991 Dec;45(6):702–713. [PubMed]
  • Peters W, Robinson BL. The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. Ann Trop Med Parasitol. 1984 Oct;78(5):459–466. [PubMed]
  • Prasad RN, Prasad H, Virk KJ, Sharma VP. Application of a simplified in-vivo test system for determining chloroquine resistance in Plasmodium falciparum. Bull World Health Organ. 1990;68(6):755–758. [PubMed]
  • Pukrittayakamee S, Viravan C, Charoenlarp P, Yeamput C, Wilson RJ, White NJ. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother. 1994 Mar;38(3):511–514. [PMC free article] [PubMed]
  • RAMAKRISHNAN SP, PRAKASH S, CHOWDHURY DS, BASU PC. Studies on Plasmodium berghei Vincke and Lips, 1948. XXIX. The size of parasite population and its relation to the selection of a strain resistant to sulphadiazine. Indian J Malariol. 1961 Jun;15:95–106. [PubMed]
  • Rieckmann K, Suebsaeng L, Rooney W. Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand. Am J Trop Med Hyg. 1987 Sep;37(2):211–216. [PubMed]
  • ROLLO IM. Daraprim resistance in experimental malarial infections. Nature. 1952 Sep 6;170(4323):415–415. [PubMed]
  • Ross JP. The Surgery of Arterial Disease and Injury. Br Med J. 1946 Jan 5;1(4435):1–4. [PMC free article] [PubMed]
  • SHUTE PG, MARYON M. A contribution to the problem of strains of human plasmodium. Riv Malariol. 1954 Jun;33(1-3):1–21. [PubMed]
  • Silamut K, White NJ. Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):436–443. [PubMed]
  • Smithuis FM, van Woensel JB, Nordlander E, Vantha WS, ter Kuile FO. Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother. 1993 Sep;37(9):1977–1981. [PMC free article] [PubMed]
  • ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993 Apr 24;341(8852):1044–1049. [PubMed]
  • ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992 Dec;166(6):1393–1400. [PubMed]
  • ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):660–664. [PubMed]
  • ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992 Dec;166(6):1393–1400. [PubMed]
  • Turaman C, Basco LK, Le Bras J. Evaluating the efficacy of chloroquine in febrile Guinean children infected with Plasmodium falciparum by a simplified in vivo test. Bull World Health Organ. 1992;70(4):477–480. [PubMed]
  • Watt G, Shanks GD, Phintuyothin P. Prognostic significance of rises in parasitaemia during treatment of falciparum malaria. Trans R Soc Trop Med Hyg. 1992 Jul-Aug;86(4):359–360. [PubMed]
  • White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol. 1992 Jul;34(1):1–10. [PMC free article] [PubMed]
  • White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother. 1992 Nov;30(5):571–585. [PubMed]
  • White NJ, Chapman D, Watt G. The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):590–597. [PubMed]
  • White NJ, Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):767–777. [PubMed]
  • White NJ, Krishna S, Waller D, Craddock C, Kwiatkowski D, Brewster D. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet. 1989 Dec 2;2(8675):1313–1316. [PubMed]
  • White NJ, Miller KD, Churchill FC, Berry C, Brown J, Williams SB, Greenwood BM. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med. 1988 Dec 8;319(23):1493–1500. [PubMed]
  • Yayon A, Vande Waa JA, Yayon M, Geary TG, Jensen JB. Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. J Protozool. 1983 Nov;30(4):642–647. [PubMed]
  • Zhang Y, Asante KS, Jung A. Stage-dependent inhibition of chloroquine on Plasmodium falciparum in vitro. J Parasitol. 1986 Dec;72(6):830–836. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)